Arcturus Therapeutics reported continued progress in its rare disease pipeline, particularly with ARCT032 and ARCT810, and regained global rights to its self-amplifying mRNA platform and COVID vaccine. While revenue decreased due to a collaboration termination, the company maintains a strong cash position and outlined future milestones, indicating a mixed but strategically focused outlook.
Arcturus Therapeutics' Q2 2026 earnings call provided updates on its rare disease pipeline, ARCT032 for cystic fibrosis and ARCT810 for OTC deficiency, with both programs showing advancement and enrollment completion. A significant development is the regaining of global rights to its mRNA platform and COVID vaccine, Kostaive, following the termination of its collaboration with CSL Seqirus. This gives Arcturus greater control over its vaccine assets, which could be a long-term opportunity for commercialization and partnerships, but it also led to a decrease in current revenue. The company's strong cash position and upcoming Phase 3 decision for ARCT032 in Q4 2026 are key short-term catalysts, while the strategic control over its vaccine portfolio presents a long-term opportunity for growth and partnerships.